SONN
Closed
Sonnet Biotherapeutics Holdings Inc
1.21
-0.03 (-2.42%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.24
Day's Range: 1.21 - 1.28
Send
sign up or login to leave a comment!
When Written:
0.328
Sonnet Biotherapeutics Holdings Inc. is a clinical-stage biopharmaceutical company that develops innovative immunotherapies for the treatment of cancer and other diseases. The company's proprietary platform technology, SONNET, is designed to enable the development of targeted, bi-specific, and multi-specific antibody-based therapeutics. These therapeutics are designed to harness the power of the immune system to selectively target and destroy cancer cells while leaving healthy cells unharmed.
Sonnet Biotherapeutics Holdings Inc. is headquartered in Princeton, New Jersey, and was founded in 2011. The company's lead product candidate, SON-1010, is a bi-specific antibody that targets both IL-2 and CD73, two proteins that are overexpressed in multiple types of cancer. SON-1010 is currently in a Phase 1 clinical trial for the treatment of advanced solid tumors.
In addition to its lead product candidate, Sonnet Biotherapeutics Holdings Inc. has a pipeline of other immunotherapies in various stages of development, including bi-specific and multi-specific antibodies targeting other cancer-related proteins. The company's goal is to develop a broad portfolio of innovative immunotherapies that can improve the lives of patients with cancer and other diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Sonnet Biotherapeutics Holdings Inc. is headquartered in Princeton, New Jersey, and was founded in 2011. The company's lead product candidate, SON-1010, is a bi-specific antibody that targets both IL-2 and CD73, two proteins that are overexpressed in multiple types of cancer. SON-1010 is currently in a Phase 1 clinical trial for the treatment of advanced solid tumors.
In addition to its lead product candidate, Sonnet Biotherapeutics Holdings Inc. has a pipeline of other immunotherapies in various stages of development, including bi-specific and multi-specific antibodies targeting other cancer-related proteins. The company's goal is to develop a broad portfolio of innovative immunotherapies that can improve the lives of patients with cancer and other diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








